09:25 AM EDT, 09/13/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) said Friday that initial results from a certain group of patients with platinum-resistant ovarian cancer showed "signs of clinical activity" in a phase 1/2 trial of the TransCon IL-2 beta/gamma drug in combination with chemotherapy.

"Anti-tumor clinical responses" were observed in 29% of the 18 patients in a platinum-resistant ovarian cancer group, suggesting "meaningful signs of anti-tumor activity," Ascendis said.

TransCon IL-2 beta/gamma was generally well-tolerated with the most commonly observed adverse events being fatigue, thrombocytopenia, neutropenia, and anemia, the company said.

Price: 113.65, Change: -0.16, Percent Change: -0.14